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In July 2017, the US Food and Drug Administration (FDA) announced a proposal to limit all cigarettes
to thosewith very low nicotine content (VLNC) as a key part of the comprehensive plan for nicotine
regulation. The objectives of that plan are to promote smoking cessation in existing adult smokers
and to help keep those who are experimenting, especially young people, from progressing to
persistent smoking.1 For more than a decade, the FDA has funded research on the use of VLNC
cigarettes among the general population of smokers. Higgins et al2 examined the changes in
consumption of VLNC cigarettes in 3 groups drawn from vulnerable populations: individuals with
affective disorders, those with opioid use disorder, and women with socioeconomic disadvantage.
These populations have disproportionately high rates of smoking and low rates of cessation and
warrant special attention as a matter of social justice as well as health. Paid volunteers were
randomized to receive experimental cigarettes with normal nicotine content or cigarettes with 2
levels of VLNC. After a week of smoking to establish a baseline, participants were given their assigned
cigarettes for 12 weeks. Participants received twice the number of baseline cigarettes used to allow
for the possibility theymight smokemore. However, participants in the VLNC groups often used their
own brand of cigarettes, despite instructions not to do so, complicating interpretation of results. The
primary outcome was that those in the 2 VLNC groups smoked about 5 to 7 cigarettes less per day
than control participants. There were small decreases in carbonmonoxide and nicotine dependence
in the VLNC groups, but, importantly, there was no difference in smoking cessation. The suggested
conclusion of the study by Higgins et al2 is that “reducing nicotine content of cigarettes to low levels
has the potential to benefit populations that are vulnerable to tobacco use, addiction, and
smoking-attributable morbidity andmortality.”
Is this strong policy statement warranted by the findings in this study?We think not. Themain
finding—a modest within-trial reduction in cigarette consumption—does not support the objectives
of the comprehensive plan for nicotine regulation at a national level. The ability of the VLNC
intervention to promote smoking cessationwas specifically tested at week 12when participants were
offered $100 to abstain from smoking for 24 hours, a modest goal given that most smokers who
abstain for 24 hours relapse, and smokers do not get such offers in real life. The VLNC intervention
did not result in smoking cessation.2 This raises serious questions about the conclusion that a VLNC
cigarette policy alone would promote smoking cessation or reducemorbidity andmortality. The
health benefits of VLNC cigarettes remain unclear. Reductions in the level of NNAL
(4-[methylnitrosamino]-1-[3-pyridyl]-1-butanol), a biomarker for tobacco smoke carcinogens, were
small, and 1 group (opioid users) experienced an increase in the level of NNAL.2
To effectively support policy change, research that considers the broad context of the whole
FDA strategic plan is required.1 Areas to be considered include evidence from implementation studies
of real-world use rather than ideal conditions, unintended negative consequences associated with
VLNC cigarettes, complex market forces, evolving safer nicotine products, complex user behaviors,
and even black markets. Consideration of black markets is particularly useful when attempting to
make nicotine, which is an avidly sought-after commodity for over 30million smokers in the US and 1
billion smokers worldwide, so much harder to obtain in legitimate cigarette products.3
Any VLNC cigarette policy needs to be considered—as the FDA intended—as just 1 part of a
broader initiative to move nicotine seekers completely away from smoking deadly combusted
cigarettes. Cigarettes with VLNC are at best half of the policy. The FDA put it plainly the “new tobacco
strategy has two primary parts: reducing the addictiveness of combustible cigarettes while
+ Related article
Author affiliations and article information are
listed at the end of this article.
Open Access. This is an open access article distributed under the terms of the CC-BY License.
JAMA Network Open. 2020;3(10):e2019367. doi:10.1001/jamanetworkopen.2020.19367 (Reprinted) October 20, 2020 1/3
Downloaded From: https://jamanetwork.com/ on 10/21/2020
recognizing and clarifying the role that potentially less harmful tobacco products could play in
improving public health.”1(p1112)
The second part of the FDA’s comprehensive nicotine plan is making available substantially less
harmful products by which nicotine can be delivered without the toxic effects of tobacco smoke.
Themost commonway of using nicotine without smoke, indeed without tobacco, is nicotine vaping
(e-cigarettes), which decreases exposure to harmful chemicals,3,4 emits no carbonmonoxide, may
facilitate the switch from cigarettes to medicinal nicotine or nicotine products without smoke,3,4 can
complement the use of VLNC cigarettes,5 andmay accelerate saving smoker’s lives.3,4 It is
encouraging to note that the FDA has recently authorized amodified-risk marketing order for a
product that heats but does not burn tobacco and will be reviewing the safety of other nicotine
vaping products in the near future, allowing for clearer communication to the public that smokeless
nicotine product use may be associated with lower exposure to harmful chemicals. In terms of
smoking behavior, to encouragemore smokers to switch from deadly cigarettes tomedicinal nicotine
or nicotine products without smoke, it is essential to correct misperceptions among the public,
health care clinicians, and policy makers who believe that nicotine is themost harmful component of
smoking. The FDA has stated that “Nicotine, though not benign, is not directly responsible for the
tobacco-caused cancer, lung disease and heart disease that kill hundreds of thousands of Americans
each year.”1(p1112)
Embodied in FDA’s modeling study,6 which predicted that 8.5 million smokers’ lives could be
saved by reducing the levels of nicotine in cigarettes, is the need to implement both parts of the
comprehensive nicotine regulation plan. Harm reduction keeps the focus squarely where it should
be: on reducing the severe disease burden andmortality associated with smoking.1,3-6 The FDA plan
accepts that many smokers may not want or be able to achieve complete nicotine abstinence, but
they do not have to die from the method of nicotine delivery. The perfect public health outcome
would be for people who are already using any form of nicotine to stop all use and abstain for their
lifetime or, better still, never to start. But a pragmatic public health approach requires that realistic
alternatives to de facto nicotine prohibition be considered.3 Cigarettes are by far the most popular
yet deadly route of nicotine administration. Safer alternatives are now available along the FDA
nicotine harm continuum.1,3,4 Years of robust evidence are available for the use of nicotine
replacement therapy (NRT) as a safe way to deliver clean nicotine. But after more than 25 years, NRT
has not become a viable vehicle for displacing smoking at a scale to impact the population, partly
because of inadequate nicotine delivery and its unattractive and expensive medicinal positioning in
the market. Far more smokers try to quit by vaping nicotine than with NRT.3,4 Many former smokers
enjoy vaping nicotine and report its advantages.7,8 They find vaping nicotine to be a reasonable and
safer substitute for smoking.4,9 Informed by rigorous evidence reviews, the United Kingdom
endorses harm reduction (including vaped nicotine e-cigarettes) as part of a comprehensive tobacco
control plan.4
Whereas other fields have accepted that continued safer use of a psychoactive drugmay help
avoid more serious harm (eg, methadonemaintenance in people dependent on opiates) the tobacco
control field is not quite there yet. The combination of VLNC in deadly combusted cigarettes with
the availability of adequate alternative nicotine delivery products holds promise to rapidly reduce
smoking, which remains the leading cause of premature death in the US.10 The time has come to
rethink nicotine use. The lives of 1 billion smokers worldwide are at stake.
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